FMP

FMP

Enter

SPHS - Sophiris Bio, Inc.

Financial Summary of Sophiris Bio, Inc.(SPHS), Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of produc

photo-url-https://financialmodelingprep.com/image-stock/SPHS.jpg

Sophiris Bio, Inc.

SPHS

OTC

Inactive Equity

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302 (topsalysin), which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.

0.000001 USD

0 (0%)

About

ceo

N/A

sector

Healthcare

industry

Biotechnology

website

https://www.sophirisbio.com

exchange

OTC

Description

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302 (topsalysin), which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc...

CIK

0001563855

ISIN

CA83578Q2099

CUSIP

83578Q209

Address

1258 Prospect Street

Phone

858-777-1760

Country

US

Employee

6

IPO Date

Nov 18, 2008

Summary

CIK

0001563855

Exchange

OTC

Industry

Biotechnology

Sector

Healthcare

CUSIP

83578Q209

ISIN

CA83578Q2099

Country

US

Price

0

Beta

-33.39

Volume Avg.

16

Market Cap

0

Shares

-

52-Week

0.000001-0.000001

DCF

0

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

0

P/B

-

Website

https://www.sophirisbio.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest SPHS News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep